Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastomaPaul M. Clément, Martin J. van den Bent, Jim Looman et al.|European Journal of Cancer|2021Cited by 20
LTBK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX –M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410Martin J. van den Bent, Vassilis Golfinopoulos, Marica Eoli et al.|Neuro-Oncology|2017Cited by 14
Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastomaMartin J. van den Bent, Vassilis Golfinopoulos, Marica Eoli et al.|Neuro-Oncology|2020Cited by 8
Interim analysis of the randomized PATSGO trial evaluating the prolongation of adjuvant temozolomide in newly diagnosed glioblastoma patients.Jean‐François Baurain, Laurette Renard, Tom Boterberg et al.|Journal of Clinical Oncology|2010Cited by 2
QLIF-47. HEALTH RELATED QUALITY OF LIFE AND NEUROLOGICAL DETERIORATION FREE SURVIVAL IN INTELLANCE 2/EORTC TRIAL 1410, A RANDOMIZED PHASE II STUDY ON ABT414 IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMAPaul M. Clément, Vassilis Golfinopoulos, Martin J. van den Bent et al.|Neuro-Oncology|2017Cited by 2